N/A
Completed N=427
Life Plans Intervention Study
HIV · Chronic HIV Infection · Health Knowledge, Attitudes, Practice
Source: ClinicalTrials.gov NCT03215901 ↗
Enrolled (actual)
427
Serious AEs
0.0%
Results posted
Jun 2020
Primary outcomePrimary: Number of Participants Who Participated in HIV Testing — 69; 33; 46 Participants
Summary
The mass provision of HIV treatment in rural KwaZulu-Natal, South Africa has raised adult life expectancy by 18 years since 2003. We will conduct a population-based survey to assess young adults' beliefs about HIV, HIV treatment, and expectations for the future in the era of mass HIV treatment. Thh investigators will conduct a randomized evaluation to assess whether a short video providing young adults with information on longevity gains from HIV treatment affects young adults survival expectations, hope for the future, and health and educational behaviours, including uptake of HIV testing, the study's primary outcome.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants Who Participated in HIV Testing |
69; 33; 46 | — |
| SECONDARY Use of HIV Testing Voucher |
20; 5; 11 | — |
| SECONDARY Participation in HIV Testing or Care Services |
— | — |
| SECONDARY Attendance at Job Search Skills Workshop |
39; 17; 27 | — |
| SECONDARY Condoms Purchased |
2.2; 2.3; 2.4 | — |
| SECONDARY Money Allocated to Savings Tin |
38.6; 43.1; 39.3 | — |
| SECONDARY Change in Subjective Life Expectancy (Baseline to Immediate Post-test) |
1.3; 0.3; 0.7 | — |
| SECONDARY Subjective Life Expectancy (2 Months) |
-0.6; 0.6; 1.0 | — |
Eligibility Criteria
Inclusion Criteria
- resides in Africa Health Research Institute demographic surveillance area, specifically bounded structures to be visited during the last trimester of the surveillance in the "Southern PIPSA" area.
- member of a household in the AHRI demographic surveillance
- 18 to 25 years of age
Exclusion Criteria
- 25 years
- not a member of a household under surveillance
- not resident in the surveillance area
Data sourced from ClinicalTrials.gov (NCT03215901). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.